Published in:
Open Access
01-11-2013 | Meeting abstract
P01-050 – Anakinra in systemic JIA: single center experience
Authors:
M Pardeo, A Insalaco, C Bracaglia, R Nicolai, AE Tozzi, G Prencipe, F De Benedetti
Published in:
Pediatric Rheumatology
|
Special Issue 1/2013
Login to get access
Excerpt
Systemic juvenile idiopathic arthritis (sJIA) accounts for 10-20% of all patients with JIA. The clinical features include fever, evanescent rash, arthralgia and arthritis, myalgia, lymphadenopathy, hepatomegaly, splenomegaly and serositis. Interleukin 1 (IL-1) has been shown to be a major mediator of the inflammatory cascade that underlies sJIA (1). Treatment with anakinra, IL-1 receptor antagonist has been reported to be effective in a subset of patients with sJIA (2). …